Elestrin

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Elestrin

What is Elestrin

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone naturally produced by females. It is available in several forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. When taken orally or by injection, estradiol is usually combined with a pro-drug ester. Ethinyl estradiol (EE) is a synthetic form of estradiol that is used in most combination oral contraceptive pills. EE is more potent and has a higher bioavailability than estradiol, making it better suited for oral administration.

Estraderm

is the brand name

image of different drug pills on a surface

Elestrin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Elestrin Affects Patients

Estradiol is used to help reduce symptoms such as hot flashes and vaginal dryness. It can also increase bone density and improve your lipids (fats in your blood). Estradiol increases the production of sex hormone binding globulin (SHBG) and thyroid-binding globulin (TBG), and decreases follicle-stimulating hormone (FSH) in the pituitary gland. However, long-term use of estradiol may be linked to an increased risk of cardiovascular disease, deep vein thrombosis (DVT) and stroke, so should be avoided in those at high

How Elestrin works in the body

Estrogen is a hormone found in many tissues of the body, including the breast, uterus, ovaries, skin, prostate, bones, fat, and brain. In adult women, the ovaries produce most of the estrogen in the body. After menopause, though, the adrenal glands are the main source of estrogen. Estrogen has two main types: estradiol, which is stronger and more potent, and estrone. Estrogen works by binding to receptors in the body called estrogen receptors (ERα and ERβ). This causes a reaction in the cells that produces proteins which give estrogen its effects. In postmen

When to interrupt dosage

The dosage of Elestrin is contingent upon the diagnosed condition, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The magnitude of dosage is contingent upon the listed method of administration in the subsequent table.

Condition

Dosage

Administration

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Elestrin Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Elestrin.

Common Elestrin Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Elestrin Toxicity & Overdose Risk

Tests in rats have shown that estradiol can be toxic in doses of 0.003 mg/kg per day or higher. The toxic dose for women is 21 mg/kg per day, and for rats it is 960 mg/kg. An overdose of estradiol can lead to nausea, vomiting, abdominal pain, breast tenderness, blood clots, and vaginal bleeding. If a person has overdosed on estradiol, it is best to stop taking the drug and seek supportive care.

image of a doctor in a lab doing drug, clinical research

Elestrin Novel Uses: Which Conditions Have a Clinical Trial Featuring Elestrin?

867 active studies are investigating the potential of Elestrin to provide treatment for Osteoporosis, an absence of menstruation in the preceding 6 months and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

19 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

19 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

4 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

71 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Hormone Replacement Therapy

0 Actively Recruiting

Elestrin Reviews: What are patients saying about Elestrin?

5

Patient Review

6/9/2013

Elestrin for Low Estrogen After Operation to Remove Ovaries

Elestrin is a fantastic product that is really easy to use. You'll need to give it some time to work properly, but it's definitely worth it! I'm so glad I found this product - it's given me my life back!

5

Patient Review

3/13/2013

Elestrin for "Change of Life" Signs

My doctor prescribed this and it has helped me so much, especially because I wanted something that was bio-identical.

4.7

Patient Review

7/8/2010

Elestrin for Low Estrogen After Operation to Remove Ovaries

Elestrin gel has been a godsend. I use it twice daily as directed, and have seen significant improvements in my quality of life. No more hot flashes or mood swings!

4.7

Patient Review

2/4/2011

Elestrin for Low Estrogen After Operation to Remove Ovaries

Since starting this medication, I have seen a significant reduction in hot flashes and headaches. Additionally, my mood swings have improved. This has been an overall effective treatment for me.

4.7

Patient Review

5/6/2014

Elestrin for "Change of Life" Signs

Elestrin has helped me feel like myself again. I very rarely have hot flashes and my emotions are more stable.

4.7

Patient Review

11/3/2010

Elestrin for "Change of Life" Signs

I've been using this for a little over two weeks now, and it's helped me quite a bit. The patch was uncomfortable and difficult to keep on for an entire year.

4.3

Patient Review

2/28/2010

Elestrin for Low Estrogen After Operation to Remove Ovaries

The only problem I've had is that the skin on my arms has gotten darker where I apply the gel.

4

Patient Review

9/26/2013

Elestrin for Low Estrogen After Operation to Remove Ovaries

I haven't had any bad side effects, but I am curious about how long I will have to take this medication. I'm currently 57 years old. Does anyone have a similar experience or opinion on this?

3.7

Patient Review

7/23/2011

Elestrin for Low Estrogen After Operation to Remove Ovaries

I'm losing hair, which is a major bummer. I might have to stop taking this medication as a result.

2.3

Patient Review

7/8/2010

Elestrin for Low Estrogen After Operation to Remove Ovaries

I had my ovaries removed via laparoscopic surgery six days ago, and I'm still feeling pretty out of sorts. The past few days my mood has been all over the place, and I'm hoping that each day will bring more balance. This treatment seems to help a little bit, but I'm still not back to normal yet.

2

Patient Review

8/4/2012

Elestrin for Low Estrogen After Operation to Remove Ovaries

I found that this treatment made me very confused, and on the second day my brain felt numb. By the third day, I had blurred vision. I decided to stick with Premarin because I didn't like the weight gain associated with this medication.

1.7

Patient Review

8/20/2011

Elestrin for Primary Ovarian Failure

After using Elestrin for only a week as directed, I started experiencing hair loss, general malaise, and skin rashes. Needless to say, I stopped this treatment immediately.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about elestrin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a generic for Elestrin gel?

"There is no cheaper generic version of Elestrin currently available. The most common version of Elestrin is covered by 83% of insurance plans, with a co-pay of $60.00-$77.50. However, some pharmacies may offer lower prices without insurance."

Answered by AI

How much does Elestrin cost?

"The cheapest price for Elestrin is $237.74. This is 16% lower than the average retail price of $283.62."

Answered by AI

What is Elestrin gel?

"Elestrin is a prescription medication used to manage the symptoms of night sweats, hot flashes, and flushes that are often associated with menopause. It may be used alone or in conjunction with other medications. Elestrin belongs to a class of drugs called estrogen derivatives. Its safety and efficacy in children has not been established."

Answered by AI

What is Elestrin used for?

"This medication contains the female hormone estrogen. You absorb it through your skin and into your bloodstream. Doctors prescribe it to help reduce hot flashes, a symptom of menopause. Some brands of this medication can also help relieve vaginal symptoms of menopause, such asdryness, burning, and itching."

Answered by AI

Clinical Trials for Elestrin

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Elestrin clinical trials?

We made a collection of clinical trials featuring Elestrin, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Elestrin clinical trials?

We made a collection of clinical trials featuring Elestrin, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Abhinav K Jha, Ph.D.

Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA

This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.

Recruiting
Has No Placebo

City of Hope Medical Center

Jeannine M Brant

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.

Phase 2
Recruiting

City of Hope Medical Center

Rose Li

Have you considered Elestrin clinical trials?

We made a collection of clinical trials featuring Elestrin, we think they might fit your search criteria.
Go to Trials